Remaining patent years for opdivo?

When does the main Opdivo patent expire?
The key composition-of-matter patent covering nivolumab, the active ingredient in Opdivo, is set to expire in December 2027 in the United States, with several method-of-use and formulation patents running into the early 2030s [1].

Why are companies challenging the Opdivo patents?
Generic and biosimilar makers have filed Paragraph IV challenges against the remaining patents, arguing that some claims are obvious or lack sufficient written description [1].

Can biosimilars enter before the main patent expires?
Under current law, biosimilars cannot launch until the 12-year regulatory exclusivity period ends and any remaining patents are either invalidated or expire, so entry before December 2027 is unlikely unless litigation succeeds [2].

How long does regulatory exclusivity last for Opdivo?
Opdivo received FDA approval in December 2014, giving it 12 years of biologic exclusivity that ended in December 2026, leaving only the remaining patent protection as the final barrier [2].

What other patents still protect Opdivo after 2027?
Bristol Myers Squibb holds additional patents on combination uses with Yervoy and on specific dosing regimens that extend into 2030–2032 [1].

Who makes Opdivo and how does it compare with Keytruda?
Bristol Myers Squibb markets Opdivo; Merck’s Keytruda is its closest competitor. Both are PD-1 inhibitors, but they differ in approved indications, dosing schedules, and companion diagnostic requirements [3].

What side effects are patients asking about?
Common questions focus on immune-related adverse events such as colitis, pneumonitis, and endocrinopathies, as well as infusion reactions [3].

[1] https://www.drugpatentwatch.com/drug/opdivo
[2] https://www.drugpatentwatch.com/drug/opdivo
[3] https://www.drugpatentwatch.com/drug/opdivo